Cabbacis Bets on FDA Nicotine Cap with Patented Hemp-Infused Cigarettes

NEW YORK, NY – September 02, 2026 – As Cabbacis CEO Joseph Pandolfino prepares to court institutional investors at the Moody Capital Disruptive Growth & Life Sciences Conference next week, the stakes could not be higher. The Niagara Falls-based firm isn't just seeking capital; it's validating a high-risk, high-reward strategy built entirely around a single, transformative regulatory proposal: the U.S. Food and Drug Administration's plan to mandate a massive reduction in the nicotine content of all cigarettes.

While major tobacco players diversify into vapes and heated tobacco products, Cabbacis (OTCQB: CABI) is making a concentrated bet on a future where traditional cigarettes are rendered non-addictive by law. The company's flagship products in development, the iBLEND™ and X95™ cigarettes, are engineered with approximately 95 percent less nicotine than their conventional counterparts. Pandolfino's upcoming presentation on September 10th is a critical milestone in the journey to commercialize this vision, moving the company from prototype to a potential profit-generating enterprise in a radically reshaped market.

A Strategy Synced with Regulation

Cabbacis's entire commercialization blueprint is predicated on the finalization and enforcement of a proposed FDA rule announced in January 2025. This landmark regulation would cap nicotine in cigarettes and certain other combusted tobacco products at a minimally or non-addictive level of 0.7 milligrams per gram of tobacco—a stark drop from the 17.2 mg/g average found in 2017. The FDA's goal is to sever the cycle of addiction, projecting that such a rule could prompt nearly 13 million people to quit smoking within a year and prevent 48 million young people from ever starting by 2100.

While the rule's implementation has been delayed by a regulatory freeze, its potential to fundamentally disrupt the $80 billion U.S. cigarette market is undeniable. Industry groups have pushed back, with a study commissioned by the National Association of Tobacco Outlets forecasting dire economic consequences, including billions in lost revenue and nearly 100,000 job losses. It is within this contested landscape that Cabbacis has positioned itself not as a defender of the old guard, but as a purveyor of the new standard.

The company’s products are designed to be compliant from day one. By developing very-low-nicotine content (VLNC) cigarettes, the firm aims to provide a viable alternative for smokers who, under the proposed rule, would no longer be able to purchase addictive conventional cigarettes. This proactive alignment is the core of Cabbacis's investment thesis and its primary differentiator in a crowded field.

The iBLEND™ Proposition: Hemp, Patents, and Early Promise

Beyond simply reducing nicotine, Cabbacis is innovating on the user experience with its patented iBLEND™ technology, which combines very-low-nicotine tobacco with non-intoxicating hemp flower containing less than 0.3% THC. This isn't a gimmick; it's a calculated move to solve a key challenge for VLNC products: smoker satisfaction.

Decades of independent scientific research have validated the public health benefits of VLNC cigarettes, showing they decrease nicotine dependence and increase quit attempts without causing smokers to compensate by smoking more. However, taste and sensory experience remain critical for consumer adoption. According to company research, the addition of hemp may improve these characteristics. A pilot clinical trial conducted by the respected Rose Research Center found that iBLEND™ cigarettes significantly reduced cravings and scored highly on satisfaction. Furthermore, internal focus groups showed a 3-to-1 preference for iBLEND™ over VLNC cigarettes without hemp, with many participants rating the taste on par with or better than leading conventional brands.

Protecting this innovation is a formidable intellectual property portfolio. Cabbacis holds 36 issued patents and numerous pending applications globally, covering its unique tobacco-hemp blends in both cigarettes and vaporizer pods. This patent shield extends across key markets including the U.S., Europe, China, and Japan, covering territories where roughly two-thirds of the world's smokers reside. This IP moat is a critical asset, potentially preventing larger competitors from easily replicating its core product as the regulatory environment shifts.

The Path to Commercialization: Capital, Competition, and Leadership

Despite its strategic positioning and intellectual property, Cabbacis remains a development-stage company with a long road to profitability. It reported no revenue in 2024 or 2025, posting a net loss of over $1.5 million last year as it invested in R&D. The next major hurdle is navigating the FDA's rigorous and costly Premarket Tobacco Product Application (PMTA) process, a necessary step to gain marketing authorization in the United States. This is precisely why the upcoming investor conference is so crucial. The firm is actively raising funds through a Regulation A offering to finance these regulatory submissions and scale up for commercial launch.

The competitive landscape is dominated by giants like Philip Morris International and British American Tobacco, who are pouring billions into their own reduced-risk portfolios. However, their primary focus on heated tobacco and vaping products—categories explicitly excluded from the FDA's proposed nicotine cap—creates a distinct lane for Cabbacis. The company isn't trying to out-muscle Big Tobacco in the current market; it's positioning itself to lead a future one.

For investors weighing the considerable risks, the track record of the management team offers a compelling counterpoint. CEO Joseph Pandolfino is no stranger to this specific niche. As the founder of 22nd Century Group, he pioneered the development of genetically engineered low-nicotine tobacco and successfully guided that company to a New York Stock Exchange listing. This deep experience in plant biotechnology and the regulated tobacco space, shared by other key executives like VP of R&D Dr. Michael Moynihan, provides a level of credibility that is rare for a small OTCQB-listed firm. The presentation at the Moody Capital conference will be a test of whether this combination of regulatory foresight, product innovation, and seasoned leadership is enough to convince investors to back Cabbacis's ambitious bet on the future of tobacco.